SummaryGulf oysters and FATE get a shoutout in this episode of Melanoma Matters. Hosts James Larkin and Sapna Patel discuss the ADAPT-IT study, focusing on adaptive dosing strategies in immunotherapy for melanoma. They explore the study's design, results, and implications for clinical practice, including the potential for reduced dosing based on early response assessments. KeywordsADAPT-IT study, immunotherapy, melanoma, adaptive dosing, clinical efficacy, treatment response, toxicity management, cancer researchTakeawaysThe ADAPT-IT study explores adaptive dosing in immunotherapy.68% of patients showed favorable anti-tumor effects after two doses.Early response assessments can guide treatment decisions.The study suggests that two doses may be sufficient for some patients.There is potential for one dose to be effective in certain cases.Reimbursement policies may influence treatment strategies.Correlative studies provide insights into treatment efficacy.Management of toxicity is crucial in immunotherapy.The conversation highlights the importance of clinical intuition.Future research may refine dosing strategies further.Sound Bites"Is two cycles enough?""68% had a favorable anti-tumor effect.""Could one dose be enough?"Chapters00:00 Introduction to the ADAPT-IT Study04:12 FATE v non-FATE06:03 Clinical Implications of Early Response Assessment09:02 Results and Efficacy of the Study11:50 Discussion14:18 Exploring the Role of LDH in Treatment Decisions17:32 Correlative Studies and Future Directions20:14 Toxicity and Management Strategies22:58 Correlatives (ctDNA)30:54 Bit of good news about NADINA

Ver todos los episodios